Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. (Nasdaq: BVS) is a medical technology company that describes itself as a global leader in innovations for active healing. The Bioventus news stream features company announcements, financial updates and product milestones that reflect its focus on Pain Treatments, Surgical Solutions and Restorative Therapies.
Investors following BVS news will find regular earnings releases where Bioventus reports net sales, segment performance across Pain Treatments, Surgical Solutions and Restorative Therapies, and metrics such as net income, Adjusted EBITDA and non-GAAP earnings. These updates often include commentary on organic revenue trends, portfolio changes like the divestiture of the Advanced Rehabilitation Business, and the impact of factors such as foreign currency and tariffs.
The company also issues product and regulatory news, including announcements of U.S. Food and Drug Administration (FDA) 510(k) clearances. Recent examples include clearances for TalisMann and StimTrial, two Peripheral Nerve Stimulation products for chronic pain management that Bioventus highlights as expanding its non-opioid, minimally invasive therapy portfolio.
Bioventus news items cover capital structure and financing developments, such as the entry into a new senior secured credit agreement that refinanced prior debt, increased revolving capacity and reduced interest margins. In addition, the company regularly announces participation in major healthcare and investor conferences hosted by firms such as J.P. Morgan, Piper Sandler, Morgan Stanley and Canaccord Genuity.
For readers tracking BVS, the news page provides a centralized view of Bioventus’ financial performance, product pipeline progress, regulatory milestones and corporate events, helping contextualize how its Pain Treatments, Surgical Solutions and Restorative Therapies businesses evolve over time.
Bioventus Inc. (Nasdaq: BVS) announced FDA clearance for the neXus® SonaStar Elite® handpiece, expanding its neurosurgery ablation capabilities. This new handpiece, part of the neXus Ultrasonic Surgical Aspirator System, enhances control and versatility in soft and hard tissue removal, including tumors. The SonaStar Elite can perform procedures on both benign and malignant brain and spinal tumors. Bioventus emphasizes its commitment to developing innovative, market-leading technologies for improved surgical outcomes.
Bioventus Inc. (NASDAQ: BVS) is set to report its financial results for the second quarter of fiscal year 2022 on August 11, 2022, before the market opens. Management will host a conference call at 8:30 a.m. Eastern Time to discuss results and provide a business update. Investors can participate by calling 1-833-636-0497 domestically or +1-412-902-4241 internationally. A live webcast will be available in the Investor Relations section of the company's website and will be archived for replay until August 10, 2023.
Bioventus (BVS) has successfully completed its acquisition of CartiHeal, enhancing its portfolio in the treatment of osteoarthritis and knee defects. This strategic move positions Bioventus to leverage CartiHeal's Agili-C implant, which has shown superiority in clinical trials over current treatments like microfracture and debridement. With approximately 650,000 U.S. patients undergoing such procedures annually, the acquisition aims to delay total knee replacements and supports Bioventus’ growth goals of sustained double-digit revenue increases. Adjusted earnings per share guidance will be provided in the upcoming Q2 earnings call.
Bioventus Inc. (Nasdaq: BVS) has amended its acquisition agreement for CartiHeal, reducing the upfront cash payment to $50 million, down from $315 million. The remainder, $215 million, will be deferred to CartiHeal stockholders based on milestone achievements, payable in five tranches from 2023 to 2027. Bioventus aims to finance the acquisition through additional debt, while expecting to close the deal by the end of July 2022. The amendment is viewed as beneficial, allowing continued investment in growth initiatives while maintaining financial flexibility.
Bioventus reported Q1 2022 financial results, with net sales of $117.3 million, a significant increase of 43.4% year-over-year. However, the company saw a net loss of ($14.8) million, contrasting sharply with a net income of $24.5 million in the same period last year. Adjusted EBITDA was $7.1 million, down from $11.1 million in Q1 2021. Looking ahead, Bioventus reaffirmed its full-year guidance, expecting net sales between $545 million to $565 million.
Bioventus (Nasdaq: BVS) has withdrawn its offering of senior notes due to unfavorable market conditions, prioritizing the interests of stakeholders. The Company is considering alternative financing methods to fund its call option for the acquisition of CartiHeal Ltd. CEO Ken Reali expressed optimism about growth drivers leading to sustained double-digit growth. Bioventus reaffirmed its 2022 net sales guidance of $545 million to $565 million and adjusted EBITDA guidance of $94 million to $107 million, indicating strong operational performance despite the debt offering withdrawal.
Bioventus (Nasdaq: BVS) has secured a nationwide contract with Cigna® effective July 1, 2022, offering access to its knee osteoarthritis treatments, DUROLANE and GELSYN-3. DUROLANE, a single-injection treatment, will be exclusive to Cigna patients, while GELSYN-3 will be among two multi-injection options available. Both products are hyaluronic acid-based therapies designed to alleviate knee OA pain, addressing the degeneration of joint tissues. Tim Donovan, Bioventus Vice President, expressed confidence in the therapeutic benefits of these products for Cigna members.
Bioventus (Nasdaq: BVS) announced preliminary financial results for Q1 2022, projecting net sales between $116.5 million to $118.5 million, marking a 42% to 45% increase compared to the prior year. Despite strong sales growth in Pain Treatments and recovering Surgical Solutions revenue, the company expects a net loss of $(19.4 million) to $(19.0 million). Adjusted EBITDA is estimated at $6.8 million to $7.3 million. The results are preliminary and subject to change, particularly as Bioventus integrates its upcoming acquisition of CartiHeal.
Bioventus Inc. (Nasdaq: BVS) announced plans to offer $415 million in senior notes due 2027, subject to market conditions. The proceeds will fund its acquisition of CartiHeal, repay some borrowings, and cover offering expenses. The Issuer requires the acquisition to close within 75 days; otherwise, all notes will be redeemed. Concurrently, amendments to credit facilities will be sought to support the offering and acquisition. The notes will be offered to qualified institutional buyers in an exemption under the Securities Act, without registration.
Bioventus (BVS) will report its Q1 2022 financial results on May 10, 2022, before market opening. Following the report, management will host a conference call at 8:30 a.m. ET to discuss the results and provide a business update. Participants can join via a domestic call at 1-844-945-2085 or international at +1-442-268-1266, using access code 1795461. A live webcast and materials will be available on the Investor Relations section of their website, with archived access until May 9, 2023.